Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Down 42.8% in May

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a large drop in short interest in May. As of May 15th, there was short interest totaling 368,665 shares, a drop of 42.8% from the April 30th total of 644,870 shares. Currently, 1.7% of the shares of the stock are short sold. Based on an average trading volume of 1,050,694 shares, the short-interest ratio is currently 0.4 days.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Wednesday, May 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Biorestorative Therapies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC grew its holdings in shares of Biorestorative Therapies by 102.4% during the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after buying an additional 12,319 shares during the last quarter. DRW Securities LLC purchased a new position in Biorestorative Therapies during the fourth quarter worth about $55,000. Finally, Citadel Advisors LLC purchased a new position in Biorestorative Therapies during the third quarter worth about $152,000. 69.38% of the stock is owned by institutional investors.

Biorestorative Therapies Price Performance

NASDAQ BRTX traded down $0.05 during mid-day trading on Tuesday, reaching $0.35. 4,668,050 shares of the stock were exchanged, compared to its average volume of 11,686,646. Biorestorative Therapies has a one year low of $0.16 and a one year high of $2.05. The stock has a 50 day simple moving average of $0.26 and a 200-day simple moving average of $0.66. The stock has a market cap of $9.03 million, a P/E ratio of -0.33 and a beta of 0.29.

Biorestorative Therapies (NASDAQ:BRTX) last announced its earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. Biorestorative Therapies had a negative net margin of 3,088.27% and a negative return on equity of 508.42%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.31 million. Sell-side analysts anticipate that Biorestorative Therapies will post -0.66 EPS for the current fiscal year.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.